Recent discoveries have identified that innate lymphoid cell 2 subset (ILC2s) dysregulation is a conserved feature of obesity and manipulation of the IL-33/ILC2 axis may lead to therapies for this disease (72). This evidence concerns the gene IL33 and obesity disorder.